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 Cellular proteins are degraded by the ubiquitin-proteasome system (UPS) in a precise and timely
fashion. Such precision is conferred by the high substrate specificity of ubiquitin ligases. Identification
of substrates of ubiquitin ligases is crucial not only to unravel the molecular mechanisms by which the
UPS controls protein degradation but also for drug discovery purposes because many established UPS
substrates are implicated in disease. We developed a combined bioinformatics and affinity purification–
mass spectrometry (AP-MS) workflow for the system-wide identification of substrates of SCFbTrCP, a
member of the SCF family of ubiquitin ligases. These ubiquitin ligases are characterized by a multi-
subunit architecture typically consisting of the invariable subunits Rbx1, Cul1, and Skp1, and one of 69
F-box proteins. The F-box protein of this member of the family is bTrCP. SCFbTrCP binds, through theWD40
repeats of bTrCP, to the DpSGXX(X)pS diphosphorylated motif in its substrates. We recovered 27 pre-
viously reported SCFbTrCP substrates, of which 22 were verified by two independent statistical proto-
cols, thereby confirming the reliability of this approach. In addition to known substrates, we identified
221 proteins that contained the DpSGXX(X)pS motif and also interacted specifically with the WD40
repeats of bTrCP. Thus, with SCFbTrCP, as the example, we showed that integration of structural infor-
mation, AP-MS, and degron motif mining constitutes an effective method to screen for substrates of
ubiquitin ligases. /stke o
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Relative to most other protein posttranslational modifications (PTMs),
ubiquitylation is unique because ubiquitin can be conjugated to a substrate
protein in various chain linkages through which the modified substrates
are sorted to different cellular fates (1). Substrates polyubiquitylated with
Lys48 linkages are recognized and degraded by the 26S proteasome (2).
Target substrates are modified by the sequential actions of a ubiquitin-
activating enzyme (E1), a ubiquitin-conjugating enzyme (E2), and a ubiqui-
tin ligase (E3). The huge repertoire of more than 700 E3 ubiquitin ligases
in mammals provides the specificity required for the recognition of diverse
substrates (3, 4). Because numerous substrates targeted by the ubiquitin-
proteasome system (UPS) are oncoproteins or tumor suppressors, which
are potential targets for cancer therapy (5, 6), it is crucial to develop high-
throughput assays to identify the complete repertoire of substrates of spe-
cific E3 ubiquitin ligases.
Because E3 ubiquitin ligases, as well as other modifying enzymes, are
believed to interact transiently with their substrates in a “kiss-and-run”
manner (7), researchers tend to assay the products of the enzymatic activ-
ity rather than the enzyme-substrate interactions. To this end, quantitative
proteomics methods are widely used because they allow the identification
and quantitation of protein substrates with relatively high throughput. For1Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomo-
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www.example, an E3 ubiquitin ligase can be perturbed by RNAi (RNA inter-
ference), chemical inhibitors, or genetic manipulations, whereafter the per-
turbed samples and controls may be analyzed by quantitative mass
spectrometry (MS) for any change in protein abundance or the amount
of PTM-modified proteins (8–10). The availability of an antibody that rec-
ognizes diglycine residues, derived from ubiquitin after trypsin cleavage
(11), enables the isolation and identification by MS of ubiquitylated pep-
tides, thereby providing information about the site of ubiquitylation to
complement quantitative assays (12, 13).
Alternative approaches based on affinity purification followed by mass
spectrometry (AP-MS) (14–16) using epitope tagging are also feasible for
such screens. In AP-MS methods, a protein of interest (bait) is fused in
frame with an epitope tag, which enables the isolation of the protein com-
plexes (preys). The affinity-purified complexes are then identified by MS.
Although AP-MS experiments have contributed to the identification of
substrates of monomeric E3s, identification of substrates of multisubunit
E3s is hampered by the weak affinity of substrates for the subunit of the
E3 that recognizes the substrate and because the complex between the sub-
strate and the recognition subunit is transient (17).
Here, we used a stringent AP-MS approach to systematically identify
substrates of SCFbTrCP, a ubiquitin ligase that targets key regulators of cell
proliferation, cell growth (15), and apoptosis (18) for proteasomal degra-
dation. SCFbTrCP consists of Skp1, Cul1, Rbx1, and the F-box protein
bTrCP that acts as a substrate recognition subunit (Fig. 1). Mammals have
two paralogs of bTrCP: bTrCP1 (also known as FBXW1) and bTrCP2
(also known as FBXW11); however, their biochemical properties appear
indistinguishable. Although more than 50 substrates of SCFbTrCP have
been identified since 1999, the list is undoubtedly incomplete. Certain
E3 ligases of the SCF family recognize their substrates through a phos-
phorylated motif called a phosphodegron. Most known SCFbTrCP sub-
strates share the canonical phosphodegron DpSGXX(X)pS, which is a
diphosphorylated motif that mediates the interaction of the substrate withSCIENCESIGNALING.org 16 December 2014 Vol 7 Issue 356 rs8 1
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 the WD40 repeats of bTrCP (Fig. 1) (19, 20). Mutation of either the phos-
phodegron or theWD40 repeats abolishes substrate binding to bTrCP (21).
The phosphodegrons of all reported SCFbTrCP substrates are conserved
in vertebrates (22).
A challenge in AP-MS analyses is discriminating bona fide interacting
partners from nonspecific protein contaminants (23). To resolve this pro-
blem, we used label-free quantitative proteomics in combination with two
different background-filtering procedures. First, we used the CRAPome
(24) software suite, which not only includes a large list of common nonspe-
cific contaminants but also provides, due to the embedded SAINT algo-
rithm, a standardized scoring scheme for ranking each prey candidate
against these contaminants (23, 25, 26). We also analyzed the data with
a second strategy based on precursor ion (MS1) intensity using theMaxQuant-
Perseus software suite (27–30), which is another method that enriches for
high-confidence interactors using label-free quantitative proteomics. By
analyzing the AP-MS data with these software tools, we discriminated
specific protein interactors from presumed background contaminants
(31) and studied dynamically regulated interactions (32–34). Using this
workflow, we identified most of the known substrates of SCFbTrCP as well
as many putative previously unknown substrates of this ubiquitin ligase.
We validated this approach by examining several putative SCFbTrCP sub-
strates by immunoprecipitation followed by immunoblotting and in vitro ubi-
quitylation assay. We envisage that this approach may be useful for
identifying substrates of other E3 ubiquitin ligases.RESULTS
Mining bTrCP substrate phosphodegron motifs in the
human proteome
We first extracted 47 phosphodegrons from reported substrates of bTrCP
(table S1) and used the MEME program to formulate a stringent consen-
sus motif (Fig. 2A). We then probed the human proteome (Swiss-Prot,
human, July 2013, 20,277 entries) using this consensus motif with the
FIMO program, which generates a P value for every motif matched (the
smaller the P value, the more closely the motif matches the consensus).
Overall, we obtained 17,779 short sequences that met the requirement
of a P ≤ 1 × 10−3 and represented 7623 proteins (table S2 and Fig. 2B).wwwThese sequences included 45 of the 47 reported phosphodegrons used for
generating the consensus sequence; the two that were not recovered were
viral protein U (Vpu) and the RNA binding protein ELAV1. Vpu is a viral
protein encoded by HIV-1. Because the human Swiss-Prot database that
we used for FIMO analysis does not contain this viral protein, the phos-
phodegron for Vpu (RAEDSGNESE) was not recovered. Our recalcula-
tion shows that the FIMO P value for this phosphodegron is 1.9 × 10−6.
The phosphodegron sequence (TNYEEAAMAI) of ELAV1 is so devi-
ated from the consensus that the FIMO P value is 0.00124, lower than the
P ≤ 1 × 10−3 cutoff, and hence is also not included.
Because FIMO P values can be used to estimate how similar each pu-
tative phosphodegron is to the consensus motif, we ranked each matched
motif according to its respective FIMO P values (lowest first, represent-
ing the closest match to the consensus motif). As expected, the top-ranking
reported phosphodegrons generally contained motifs that matched more
closely to the DpSGXX(X)pS motif, for example, eEF2K (ranked 1), CTNNB1
(ranked 11), DLG1 (ranked 246), and SIPA1L1 (ranked 404). For ease of
reference, we named them category I motifs. Following the SIPA1L1, we
observed a sharp drop in the ranking for motifs derived from substrates
such as PLK4 (ranked 1214), MYC (ranked 1426), CDC25B (ranked
2931), TWST1 (ranked 3778), and MCL1 (ranked 5218), which have less
canonical motifs. The second group is termed category II motifs.
To further refine and corroborate our motif analysis, we queried the
PhosphoSitePlus repository (35), which contains phosphoproteomics and
ubiquitomics data. In total, we found 3881 phosphorylation sites reported
for our putative degrons. This analysis revealed that 46% (3507 of 7623)
of the proteins with putative degrons have at least one ubiquitylation site
(table S2). However, because of the low abundance of some modifications
at specific sites and limitation of proteomics technology, we failed to find
matching phosphoproteomics data for some well-characterized SCFbTrCP
substrates, such as PER1, WEE1, EPOR, CPEB-1, PLK4, and FANCM.
Evolutionary conservation can be used to distinguish between functional
and nonfunctional motifs (36–38), and thus, we subjected each bTrCP
degron to a conservation analysis. Among the 45 known degrons identi-
fied in our experiment, 42 degrons had a conservation score ≥0.7 between
human and mouse orthologs (table S2). However, only 23 degrons had a
conservation score ≥0.7 between human and fish, and only 1 degron
(SYLDSGIHSG) for CTNNB1 was conserved between human and Dro-
sophila. This analysis indicated that bTrCP mainly functions in vertebrates,
although its ortholog (called Slimb) also exists in flies. By setting a con-
servation score of 0.7 as observed in human and mouse orthologs, we re-
duced the total 17,779 putative degrons to 13,109 (74%).
Identification of known and candidate
substrates of bTrCP2
For the AP-MS experiments, we designed three different constructs encod-
ing bTrCP2 carrying N-terminal 2xFLAG and 2xHA epitope tags (Fig. 3,
A to C). The rationale of using two sequential immunoprecipitations with
two different epitope tags is to reduce the amount of background proteins
that copurify, albeit at the expense of weaker protein-protein interactions
(PPIs), which may be lost due to the high stringency inherent to this se-
quential method. We used the epitope tags without any bTrCP2-based fu-
sion protein (EV) as one negative control. The three baits consist of the
wild-type bTrCP2 (Fig. 3A), bTrCP2 (R447A) (Fig. 3B), and bTrCP2-DF
(Fig. 3C). The Arg-to-Ala mutation in bTrCP2 (R447A) is within the
WD40 b-propeller domain and abrogates the interaction with and conse-
quently ubiquitylation of SCFbTrCP substrates (19, 21); however, like the
corresponding bTrCP1 (R474A) mutant, bTrCP2 (R447A) retains the
ability to interact with other components and regulators of the SCF com-
plex (21, 39, 40). We assumed that such a single amino acid mutant servesSKP1 E2
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Fig. 1. The architecture of wild-type SCFbTrCP. SCFbTrCP consists of the core
subunits Cul1, Rbx1, and Skp1, and the F-box protein bTrCP that deter-
mines substrate specificity. Cul1 is a scaffold protein that interacts through
its N terminus with the adaptor protein Skp1 and through its C terminus with
the RING finger protein Rbx1, which in turn binds to a specific ubiquitin-
conjugating enzyme (E2). Skp1 interacts with the F-box domain of bTrCP,
which, in turn, recruits substrates through its WD40 repeats. These repeats
form a b-propeller structure, which specifically recognizes a diphosphory-
lated motif with the consensus DpSGXX(X)pS, known as phosphodegron..SCIENCESIGNALING.org 16 December 2014 Vol 7 Issue 356 rs8 2
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 as a critical negative control in the context of substrate screening, not only
because it allows selection against background contaminants but also be-
cause it enables the identification of interactors that are specific for the
WD40 domain. The bTrCP2-DF mutant carries a deletion in the F-box
motif and, when overexpressed in cells, acts as a dominant-negative mu-
tant (41, 42) because it binds substrates but cannot interact with Skp1,
Cul1, Rbx1, and the E2 enzyme.www.SCIENCESIGNALING.org 16We identified 1626 proteins in the AP-
MS experiments, 27 of which were previous-
ly reported substrates of SCFbTrCP (tables S3
and S4). Because the bottleneck for AP-MS
experiments is the selection of bona fide pro-
tein binders from an abundance of back-
ground contaminants, we predicted that most
of the 1626 proteins were nonspecific or sec-
ondary binders. To differentiate genuine PPIs
from background contaminants, we used two
distinctive quantitative proteomics filtering
tools—the CRAPome and Perseus software
suites—and compared immunopurified sam-
ples with negative controls that did not con-
tain any bait (Fig. 3D).
The CRAPome software enables back-
ground filtering using spectra count data
acquired by AP-MS (24). It consists of a
database of categorized background con-
taminants with two scoring schemes to
independently rank each pair of PPI identi-
fied by immunoprecipitation. Here, we
ranked wild-type bTrCP2, bTrCP2 (R447A),
and bTrCP2-DF individually against the
negative control (EV). For each bait-prey in-
teraction, CRAPome computed a probability-
based SAINT score (23) and a separate fold
change (FC) score (24) (table S3A). For
the wild-type bTrCP2 immunoprecipitation,
20 of the 27 reported substrates had high
SAINT scores of ≥0.90 (fig. S1 and table
S3B), suggesting that the SAINT score alone
may be sufficient to identify genuine binders.
Therefore, we filtered all PPIs fromwild-type
bTrCP2, bTrCP2 (R447A), and bTrCP2-DF
immunoprecipitations against EV with a
SAINT score ≥0.90 (fig. S1). However, this
analysis revealed that even specific binders
of bTrCP2 are not always bona fide sub-
strates, as exemplified by the immunopre-
cipitation of SCF subunits Skp1, Cul1, and
Rbx1, which all had SAINT scores ≥0.9.
The FC score not only estimates the re-
lative abundance (FC) of proteins between
two samples but also has a wider dynamic
range than the SAINT score (fig. S1). There-
fore, we computed a second value (FC ratio)
from the FC scores of wild-type bTrCP2
and bTrCP2-DF against those obtained for
bTrCP2 (R447A), which should not bind
any substrates. The FC ratio provides a de-
gree of confidence that the bound proteins
are substrates, as well as providing infor-mation that can be used to estimate binding stoichiometry. By setting a
SAINT score cutoff of 0.90 and an FC ratio cutoff of 10.00, the SCF sub-
units bTrCP2, Skp1, Cul1, and Rbx1 (SAINT score ≥0.90) were classified
as nonsubstrates, whereas 18 of the 27 reported substrates were retained
(Fig. 4A). Collectively, from the data, we defined 338 specific interactors
of the WD40 repeat region of bTrCP2 [154 for wild-type bTrCP2 and 231
for bTrCP2-DF against bTrCP2 (R447A), with 47 in common] on theA
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Fig. 2. Mining the human genome for the DpSGXX(X)pS motifs. (A) Consensus motif derived from the
phosphodegrons from reported bTrCP substrates: 47 well-characterized phosphodegrons were used
to build a consensus motif using MEME (http://meme.nbcr.net), highlighting the already known canonical
DpSGXX(X)pS sequence motif where D, S, and G are the best-conserved amino acid residues. (B) Dis-
tribution of FIMO −log P values against all possible sequence motifs in the human proteome: all 17,779
sequence motifs obtained from FIMO analysis of the human proteome are each plotted against their re-
spective −log P values. Some proteins have more than one motif, for example, WEE1 has both a category I
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 basis of the CRAPome analysis (table S3C), including 20 (18 from wild
type and 3 from DF) of 27 previously reported substrates.
To increase confidence in the identified substrates, we performed a
second filtering analysis by Perseus (43) using the normalized MS1
[label-free quantification (LFQ)] intensity (44) obtained from MaxQuant.
For each pair of interactions, we performed Student’s t tests (table
S4A and Fig. 4B). With the Perseus workflow, we statistically confirmed
20 of the 27 reported substrates (table S4B), of which 18 were signif-
icantly enriched in the wild-type bTrCP2 immunoprecipitation data and
7 in the bTrCP2-DF immunoprecipitation data. Together, we obtained
317 significant putative hits (163 for wild-type bTrCP2 and 221 for
bTrCP2-DF, with 61 in common between the two) using label-free quan-
titation (table S4C).
Overall, we identified 338 bTrCP2 substrate candidates that were
validated with the CRAPome and 317 validated with Perseus; the candi-
dates validated by both methods represented 207 proteins (Fig. 4C). Among
the 27 previously reported substrates, we confirmed 22 in the CRAPome
analysis (20 substrates) and Perseus (20 substrates), and the overlap between
them is 18 (Fig. 4D).wwwReproducibility of AP-MS experiments
We have been working toward the goal of identifying substrates of SCFbTrCP
for several years and earlier gathered data using an identical sequential im-
munoprecipitation AP protocol in conjunction with older versions of the
separation, MS, and bioinformatics technologies. These older data led to
the identification, validation, and characterization of four SCFbTrCP sub-
strates: eEF2K (21), RAPGEF2 (39), TFAP4 (40), and bHLH40e (45).
To evaluate the reproducibility of our AP-MS workflow, we reanalyzed
these older data (data set 2) using CRAPome (table S5). Because these
older experiments were performed with MS instruments that are at least
two generations older (Orbitraps Classic and Discovery) and are less sen-
sitive and lower in sequencing speed compared to the Orbitrap Elite, fewer
proteins were identified (725 in data set 2 versus 1626 in data set 1) (table
S6). Of the 725 proteins identified, 531 overlap with data set 1 (73%), in-
dicating that the AP-MS experiments are consistent and reproducible.
Upon the CRAPome analysis, we assigned 47 proteins from data set 2
as putative bTrCP substrates, of which 36 overlapped with the 154 puta-
tive substrates in data set 1. The lower number of putative substrates val-
idated by the CRAPome analysis in data set 2 reflected the lower spectraA
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Fig. 3. bTrCP constructs and work-
flow for analysis. (A) Wild-type (WT)
bTrCP with two HA (hemagglutinin)
and two FLAG tags. (B) bTrCP R447A
mutant that cannot bind substrates.
(C) bTrCP-DF mutant lacking the F-box
and that can bind substrate but cannot
interact with the other components of
the SCF complex. (D) Overview of the
experimental and bioinformatics work-
flow. bTrCP IP represents the pro-
teins coimmunoprecipitated after sequential immunoprecipitation with
HA and FLAG tags from cells expressing the WT bTrCP or one of the mu-
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 counts (due to the lower sensitivity and speed of older MS), which af-
fected calculation of the multiple CRAPome scores.
We also examined the number of reported substrates recovered. We
identified 25 previously reported bTrCP substrates from data set 2 (table
S6), of which 21 were also present in the 27 identified in data set 1. How-
ever, when we applied the stringent CRAPome filters (SAINT score ≥0.9,www.FC ratio ≥10), only 13 from data set 2 met the criteria for putative sub-
strates, of which 12 overlapped with those in data set 1. Nevertheless, eEF2K
(21), RAPGEF2 (39), TFAP4 (40), and bHLH40e (45) met the stringent
criteria for putative substrates in both data set 1 and data set 2 after re-
analysis. Therefore, the AP-MS experiments were reproducible, but illus-
trate how the continuous advancement in sensitivity and sequencing speedSA
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Fig. 4. Validation of substrate candidates.
(A) Validation by statistical analysis with
CRAPome. The distribution of the SAINT
score and the FC score ratio (FC ratio) for
the WT bTrCP and empty vector (EV) pair
versus the bTrCP (R447A) and EV pair are
shown. The SCF subunits bTrCP2, SKP1,
RBX1, and CUL1 are indicated with aster-
isks. (B) Validation by statistical analysis
with Perseus. A volcano plot from label-
free quantitative proteomics analysis of
bTrCPWT versus bTrCP (R447A) samples
is shown. Logarithmized ratios (t test dif-
ference) are plotted against the negative
logarithmic P value of the t test. Back-
ground binding proteins have a ratio close
to 1:1 and are located close to the vertical
0-line (gray dots). Red dots on the right ofSCIENCESIGNALING.org 16 Dvertical 0-line indicate significant hits for substrates because they are more enriched in the WT sample compared to the R447A mutant. Red triangles
represent reported substrates; gray triangles represent previously reported substrates that are not statistically significant in our AP-MS experiments; as-
terisks represent SCF subunits. (C) Venn diagram of the 338 candidates verified by the CRAPome analysis and 317 verified by Perseus analysis. (D) Venn
diagram of the reported substrates verified by CRAPome and Perseus analysis methods. (E) Venn diagram of the substrates analyzed with CRAPome or
Perseus but limited to those from the AP-MS data that also contained a degron motif (FIMO P ≤ 1 × 10−3) and a conservation score of at least 0.7.ecember 2014 Vol 7 Issue 356 rs8 5
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 of MS also leads to a parallel and inevitable improvement in MS data in
terms of both quality and quantity, which allows more stringent data
filtering and the recovery of more confident hits.
Integration of AP-MS and bioinformatics
prediction data
Taking the 448 specific interactors classified by each CRAPome and
Perseus analyses as input, we filtered these proteins by the presence of
motifs matching the phosphodegron consensus sequence and by the evo-
lutionary conservation of the motifs. We combined the AP-MS data with
the bioinformatics predictions by first requiring all putative substrates to
have a degron motif (FIMO P ≤ 1 × 10−3) and a conservation score of at
least 0.7 (table S7A). These additional criteria reduced the number of pu-
tative substrates in the combined CRAPome and Perseus data set from 448
to 221 (Fig. 4E and table S7A).
Next, we divided these 221 putative substrates into six bins according
to their FIMO P values (Fig. 5 and table S7B). The number of putative
substrates increased with the FIMO P value bins. Second, although con-
sisting of smaller numbers, bins with lower P values are more enriched in
reported substrates. For example, in the first (lowest) bin, eEF2K is the
only candidate in the bin and is a reported substrate (enrichment of re-
ported substrates is 100%). This is followed by the second and third bins,
both displaying 67% enrichment (two of three and six of nine candidates
in the bin represent reported substrates, respectively). In the final bin con-
taining proteins with category I motifs, there is 35% enrichment. Arranging
these candidates according to the ranks of their predicted degron motifs
(table S5B) placed DOCK7 as the last candidate in the fourth bin, and this
protein had a phosphodegron motif that was ranked 432, which is at thewww
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gested that the putative substrates within bins 1 to 4 are high-confidence
SCFbTrCP substrates, which is consistent with the recent characterization of
eEF2K as an SCFbTrCP (21).
The fifth and sixth bins contain the highest number of candidates (54
and 134, respectively) but also the lowest number of established substrates
(1 and 3, respectively). Most candidates in these bins have motifs (cat-
egory II motifs) that diverge from the canonical phosphodegron motif
of the known substrates. Although we considered the candidates with cat-
egory II motifs less confident, some candidates from these bins have been
identified as SCFbTrCP substrates, such as TFAP4 (40) (fifth bin), bHLHe40
(45) (fifth bin), and RAPGEF2 (39) (sixth bin).
Additional biochemical analysis of previously unknown
bTrCP substrates
To provide additional support that the previously unknown interactors
of bTrCP that we identified are substrates, we performed additional
biochemical analysis of two of the putative substrates of SCFbTrCP.
We selected for additional biochemical analysis RAPGEF2, a guanine
nucleotide exchange factor for the guanosine triphosphatase (GTPase)
RAP, which is involved in the development and maintenance of epithe-
lia (46–48), and TBC1D4, a Rab GTPase-activating protein, which is
involved in insulin-regulated trafficking of the glucose transporter GLUT4
(49, 50).
To test the interaction of bTrCP with RAPGEF2 and TBC1D4, we im-
munoprecipitated from human embryonic kidney (HEK) 293T cells
FLAG-tagged bTrCP1, FLAG-tagged bTrCP2, several other FLAG-tagged
F-box proteins, as well as CDH1 and CDC20, which are two WD40-
containing substrate recognition subunits of the APC/C (anaphase-promoting
complex/cyclosome) ubiquitin ligase. After immunoblotting, we observed
that bTrCP1 and bTrCP2, and not the other F-box proteins, coimmuno-
precipitated endogenous RAPGEF2 and TBC1D4 (Fig. 6A), as well as
other previously reported substrates, REST and b-catenin (also known
as CTNNB1), which served as positive controls.
The Arg447 residue located within the WD40 repeats of bTrCP2 (Arg474
in bTrCP1) is essential for the bTrCP-substrate interaction (21, 39). To assess
whether the observed interactions depended on the WD40 b-propeller
structure, we immunoprecipitated the FLAG-tagged wild-type bTrCP2
and the bTrCP2 (R447A) mutant and examined their binding to these sub-
strates. As expected, wild-type bTrCP2, but not the bTrCP2 (R447A) mu-
tant, immunoprecipitated endogenous RAPGEF2, bHLH40e (also known
as DEC1), and TBC1D4 (Fig. 6B), as well as the known SCFbTrCP sub-
strates PDCD4 and b-catenin.
If RAPGEF2 and TBC1D4 are bona fide substrates of SCFbTrCP, they
should be ubiquitylated by this ubiquitin ligase. Purified wild-type bTrCP,
but not the inactive bTrCP-DF mutant, induced the ubiquitylation of
TBC1D4 (Fig. 6C) and RAPGEF2 (39) when assayed in vitro with other
subunits of the SCF complex. Thus, these data indicated that RAPGEF2
and TBC1D4 can be ubiquitylated by SCFbTrCP.
Identification of putative regulators or nonsubstrate
interactors of SCFbTrCP
In addition to identifying putative substrates of bTrCP, our CRAPome and
Perseus analyses also indicated that proteins that are not substrates of
bTrCP but instead interact with this F-box protein were also enriched in
the AP-MS analysis. For example, the SCF core subunits Skp1 and Cul1
were enriched, but these are not substrates of bTrCP. The interaction of
Skp1 and Cul1 with bTrCP was readily detected by coimmunoprecipi-
tation from HEK293T cells expressing FLAG-tagged wild-type bTrCP2
or bTrCP2 (R447A). We found that HUWE1 and UBR5 (also known as1 3
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Fig. 5. Distribution of putative substrates by binned FIMO P values. Dividing
the 221 candidates into six bins according to their FIMO P values. All can-
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 EDD1), both of which are components of other E3 ubiquitin ligases, had
AP-MS profiles similar to Skp1 and Cul1 (tables S3A and S4A). Therefore,
we tested if HUWE1 and UBR5 coimmunoprecipitated with both wild-
type bTrCP2 and bTrCP2 (R447A) (Fig. 6B). These results confirmed
that both HUWE1 and UBR5 are part of the bTrCP interactome, and
indicated that the interaction is independent of the substrate recognition
WD40 domain. Thus, this approach not only identified substrates of an
E3 ubiquitin ligase but, depending on the mutants used, also revealed
potential regulators or other complexes in which the E3 ubiquitin ligase
may function.
DISCUSSION
Here, we showed that searching biological sequence databases for se-
quences using the MEME-FIMO software tool provides a useful initial data
set of putative E3 ubiquitin ligase substrates by identifying, scoring, and
ranking sequences that match closely to the conserved phosphodegron mo-
tif. We used the DpSGXX(X)pS phosphodegron motif extracted from
known SCFbTrCP substrates as proof of principle. This bioinformatics tool
also captures proteins with phosphodegron that diverged in sequence from
the canonical SCFbTrCP phosphodegron; these category II motifs had higher
FIMO P values. To minimize the number of possible candidates, we at-
tempted to match the short sequences to PhosphoSitePlus; however, because
of the incomplete repository, the phosphorylation status of some of these
motifs could not be confirmed by this method. Therefore, we applied evo-www.lutionary conservation to reduce the 17,779 predicted candidates to 13,109
sequences (6091 proteins).
To further limit the substrate repertoire, we used AP-MS to identify
proteins that interacted with bTrCP2. To confidently discern genuine in-
teractions from background contaminants, we analyzed the AP-MS data
using the spectra count–based CRAPome and MS1 intensity–based Per-
seus software tools to validate the quantitative immunoprecipitation results.
We found that, although there was only a modest 46% overall overlap be-
tween the CRAPome and Perseus results (Fig. 4C), the agreement was 82%
for the established substrates (Fig. 4D). One possible explanation for why
the ability of both CRAPome and Perseus analyses performed similarly,
with the highest overlap, for known substrates is the use of the bTrCP2
(R447A) mutant as a negative control. The interactome for the bTrCP2
(R447A) mutant theoretically resembles that of the wild-type bTrCP2, ex-
cept that it specifically lacks substrates. For these substrates, the AP-MS
result should represent an “on” (wild-type bTrCP2 or bTrCP2-DF) and
“off” [bTrCP2 (R447A)] situation regardless of whether spectra counts or
MS1 intensities are used to analyze the data. A newer version of the SAINT
algorithm may solve the moderate overlap between the CRAPome and
Perseus results for the interactome, because it is also based on MS1 quan-
titation (25). It will be interesting to reanalyze the data once this SAINT
algorithm has been incorporated into CRAPome.
We further showed that only 221 of the 448 specific bTrCP interactors
contain sequences similar to the consensus motif and at the same time
were highly conserved (Fig. 4E). Therefore, not all the specific interactorsβT
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owthat depended on the WD40 repeats are likely substrates; instead, they
may represent secondary or tertiary binders.
Many proteomics screens for substrates of E3 ubiquitin ligases are most-
ly conducted by means of monitoring protein abundance (8–10, 13), which
lack evidence pertaining to ligase-substrate interaction, because the sub-
strates can be indirectly regulated, as well as regulated by ubiquitylation.
Here, we developed an interaction proteomics approach that effectively
identifies most of the reported substrates of SCFbTrCP in a single screen.
In addition, using bioinformatics, we ranked each AP-MS candidate with
confidence based on the similarity of their putative degrons to the con-
sensus motif. At least four of the substrates that we identified from this
screen—eEF2K (21), RAPGEF2 (39), TFAP4 (40), and bHLHe40 (45)—
have been validated by various biochemical methods.
We expect that other baits can be designed on the basis of the substrate
recognition substrates for other E3 ubiquitin ligases and that this combined
AP-MS, bioinformatic, and stringent filtering approach will lead to spe-
cific and effective screens for the identification of substrates of ubiquitin
ligases, especially those of the F-box family. o
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 MATERIALS AND METHODS
Cell culture, transfection, and drug treatment
HEK293T cells were cultured in Dulbecco’s modified Eagle’s medium
(Invitrogen) with 10% fetal calf serum and penicillin-streptomycin
(100 U/ml). HEK293T cells were transfected using the polyethylenimine
(PEI) method and, 48 hours after transfection, treated with the proteasome
inhibitor MG132 (10 mM; Peptide Institute) for 5 hours.
DNA constructs
Full-length, human wild-type bTrCP2 (isoform C, NP_036432.2) carrying
HA and FLAG tags at the N terminus was cloned into the Eco RI and Not
I sites of pcDNA3 by polymerase chain reaction. The full-length construct
was then used as template to generate the bTrCP2 (R447A) mutant using
the QuikChange Site-Directed Mutagenesis kit (Stratagene) according to
the manufacturer’s directions.
The following oligonucleotides were used: forward primer, 5′-
GGGACATGAAGAATTGGTCGCATGCATCCGGTTTGATAACAAG-3′;
reverse primer, 5′-CTTGTTATCAAACCGGATGCATGCGACCAATTC-
TTCATGTCCC-3′. All constructs were verified by sequencing.
Biochemical methods
Cells were harvested and lysed with lysis buffer [50 mM tris-HCl at pH 7.4,
1 mM EDTA, 250 mM NaCl, 0.1% Triton X-100, 1 mM DTT (dithiothreitol)]
containing protease inhibitors [leupeptin (1 mg/ml), aprotinin (1 mg/ml), soy-
bean trypsin inhibitor (10 mg/ml), 0.1 mM phenylmethylsulfonyl fluoride,
tosyl lysyl chloromethyl ketone (10 mg/ml), tosylphenylalanyl chloromethyl
ketone (10 mg/ml); Sigma-Aldrich] and phosphatase inhibitors (50 mM
sodium fluoride, 100 mM sodium orthovanadate; Sigma-Aldrich) and kept
on ice for 30 min. After centrifugation at 18,500 RCF (relative centrifugal
force) in a microcentrifuge for 20 min, the supernatant was recovered and
protein concentration was determined. Laemmli sample buffer was added
to 30 mg of protein extract, which was loaded and separated by SDS–
polyacrylamide gel electrophoresis.
Antibodies
The following monoclonal antibodies were used: antibody recognizing
Cul1 (Invitrogen), antibody recognizing FLAG (Sigma-Aldrich), antibody
recognizing actin (Santa Cruz Biotechnology), antibody recognizing FLAG
M2 (Sigma-Aldrich), antibody recognizing HA 12CA5 (Covance), and anti-wwwbody recognizing b-catenin (BD Biosciences). Polyclonal antibodies were
those recognizing PDCD4 (from Bethyl Laboratories), REST (Millipore),
FLAG (Sigma-Aldrich), and TBC1D4 (Cell Signaling Technology).
bTrCP2 immunopurification
HEK293T cells grown in 15-cm dishes were transfected with pcDNA3-
2xFLAG-2xHA-bTrCP2 and treated with 10 mMMG132 for 5 hours. Cells
were harvested and subsequently lysed in lysis buffer [50 mM tris-HCl
(pH 7.5), 150 mM NaCl, 1 mM EDTA, and 0.5% NP-40]. bTrCP2 was
immunopurified with the mouse antibody against FLAG M2 coupled to
an agarose resin (Sigma-Aldrich). After washing, proteins were eluted
by competition with FLAG peptide (Sigma-Aldrich). The eluate was then
subjected to a second immunopurification with resin linked to the anti-
body against HA (12CA5 monoclonal antibody cross-linked to protein
G–Sepharose; Invitrogen).
Recovery of immunoprecipitated proteins for liquid
chromatography–MS/MS
Immunoprecipitated proteins were resuspended in a spin filter column
(Bio-Rad) and washed three times with 200 ml of phosphate-buffered sa-
line (pH 7.4) to remove residual detergent from the lysis buffer. Proteins
bound to the protein G beads were then eluted off with 100 ml of 0.5%
RapiGest reagents in 50 mM ammonium bicarbonate, followed by 100 ml
of 8 M urea in 50 mM ammonium bicarbonate (pH 8.0). Eluted proteins
were reduced with 1 mM DTTand alkylated with 5.5 mM iodoacetamide.
For tryptic digestion, proteins were first digested with endoproteinase Lys-C
(Wako Chemicals) in room temperature for 4 hours, followed by sequencing
grade–modified trypsin (Promega) overnight, after fourfold dilution with
50 mM ammonium bicarbonate. Protease digestion was stopped by addi-
tion of trifluoroacetic acid (TFA), and precipitates were removed after cen-
trifugation. Peptides were desalted using reversed-phase Sep-Pak C18
cartridges (Waters), then dried and stored at −20°C.
Liquid chromatography–MS/MS
For MS analysis, peptides were first separated with a C18 column (Zorbax)
and introduced by nanoelectrospray into the LTQ Orbitrap Elite (Thermo
Fisher) and MS/MS in data-dependent decision tree mode (collision-
induced dissociation/electron transfer dissociation) as described previously
(51, 52).
MS data analysis
MS raw files were analyzed using MaxQuant (version 1.4.0.8) with the
match between runs and LFQ options selected. MS/MS spectra, top 8
selected in 100-dalton bin, were searched against the UniProt Human
database (version 2013-07, 20,277 entries). Trypsin/P was chosen as the
protease, cysteine carbamidomethylation was set as fixed modification,
and oxidation of methionine and acetylation of the N terminus of the protein
were set as variable modifications. Peptide tolerance was initially set to
20 ppm for first search and 4.5 ppm after recalibration;MS/MS tolerance
was set to 0.5 dalton. All peptide-spectrum matches (PSMs) and proteins
were validated with 1% false discovery rate (FDR). Only PSMs with a
minimum length of 7 amino acids were kept.
Post-acquisition data analysis: CRAPome and
Perseus analyses
Before analysis using the CRAPome or Perseus software suite, the
“proteingroups.txt” table generated by MaxQuant was filtered for con-
taminants and highly abundant proteins (such as keratins, tubulins, and
ribosomal proteins), reverse hits, number of unique peptides (>0), and num-
ber of peptides (>1). Subsequently, analysis and filtering using the CRAPome.SCIENCESIGNALING.org 16 December 2014 Vol 7 Issue 356 rs8 8
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 software suite were performed essentially as described (24). To discriminate
bona fide protein interactors of bTrCP2 from the background, we set a
SAINT score threshold of 0.9. Subsequently, to identify the putative sub-
strates from this pool of specific interactors, we computed the ratios (FC
ratios) for the FC-B scores between the wild-type bTrCP2 or bTrCP2-DF
against the bTrCP2 (R447A) mutant. For the convenience of FC-ratio estima-
tion, missing values in FC-B scores were imputed with a minimal value of 0.1.
For analysis using the Perseus software suite for identifying specific
interactors of wild-type bTrCP2 or bTrCP2-DF against that of the bTrCP2
(R447A) mutant, t test–based statistics were applied on LFQ (53). First,
the LFQ values were transformed to logarithm (log2), and the resulting
Gaussian distribution of the data was used for imputation of missing
values by normal distribution (width = 0.3, shift = 2.5). Statistical outliers
were then determined using a two-tailed t test followed by multiple testing
corrections with a permutation-based FDR method.
In vitro ubiquitylation assay
HEK293T cells were transfected with HA-tagged TBC1D4 along with
His-Skp1,Myc-Rbx1, Cul1, and either FLAG-bTrCP1 or FLAG–bTrCP1-DF
using the PEI transfection method. Forty-eight hours after transfection,
MG132 (10 mM)was added and cells were harvested after 5 hours. Immuno-
precipitation using FLAG resin was carried out as described above. Two final
washeswithQAbuffer [10mMtris-Cl (pH7.5), 100mMKCl, 1mMMgCl2,
0.1mMCaCl2, 1mMDTT]were performed in addition to the lastwasheswith
lysis buffer. After the last wash, 10 ml of the invitro ubiquitylation mix contain-
ing 50mM tris (pH 7.6), 5 mMMgCl2, 0.6 mMDTT, 2 mMATP (adenosine
5′-triphosphate), E1 (1.5 ng/ml) (Boston Biochem), Ubc3 (10 ng/ml), ubiquitin
(2.5 mg/ml) (Sigma-Aldrich), and 1 mMubiquitin aldehyde was added. The re-
actions were incubated at 30°C for 90 min and analyzed by immunoblotting.
Motif searching
The bTrCP-binding motif analysis was performed with the MEME and
FIMO tools from the MEME software suite (54) (http://meme.nbcr.net).
We first identified the proper bindingmotif and then scanned the full human
proteome for its presence. The motif identification was performed with
theMEME (55) program on the set of 47 bTrCP-binding phosphorylated
peptides publicly deposited. The motif width was set to 10 residues and
specified the occurrences to one per sequence for the MEME search
parameters.We then used themotif and position-specific probability matrix
generated by MEME to rescan the Swiss-Prot (human, July 2013, 20,277
entries) with the FIMO (56) program. All potential binding siteswithP≤
1 × 10−3 were reported.
Phosphorylation and ubiquitination sites matching
The phosphorylation sites and ubiquitylation sites in predicted bTrCP-
binding sites and corresponding proteins were mapped by searching the
PhosphoSitePlus (35) database (www.phosphosite.org; version of 2013.12.06).
bTrCP-binding site conservation analysis
Orthologous protein sequences and their alignments among human, mouse,
zebrafish, and fruit fly were downloaded from the EggNOG database’s
metazoan orthologous groups (57) (http://eggnog.embl.de/version_4.0.beta/).
The EggNOG database uses nonsupervised clustering methods to as-
sign 1133 species to more than 700,000 orthologous protein groups. We
scanned the regions of the alignment that correspond to the bTrCP-binding
motif (XXXDSGXXSX) in the corresponding human protein. We then as-
sessed whether the motif observed in a human protein was also located at
the corresponding position in any of the other three species by calculating
the percentage identity of the aligned protein sequences that corresponded
to the positions of motifs.www.SUPPLEMENTARY MATERIALS
www.sciencesignaling.org/cgi/content/full/7/356/rs8/DC1
Fig. S1. Statistical validation using the CRAPome.
Table S1. Reported phosphodegron motifs for bTrCP2.
Table S2. List of 17,779 predicted phosphodegron motifs in human proteome.
Table S3. List of proteins isolated by immunoprecipitation, categorized by CRAPome
values and sorted into the reported substrates and putative substrates (data set 2).
Table S4. List of proteins isolated by immunoprecipitation, categorized by Perseus values
and sorted into the reported substrates and putative substrates.
Table S5. List of proteins isolated by immunoprecipitation comparing wild-type bTrCP2
with R447A mutant, categorized by CRAPome values (data set 1 or old data set).
Table S6. Performance metrics of reproducibility testing.
Table S7. List of putative substrates validated by both CRAPome and Perseus analyses
combined with bioinformatics analyses.
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Fig. S1. Statistical validation using the CRAPome.  The distribution of the SAINT score and the fold-change (FC) score for wild-
type βTrCP (WT) versus empty vector immunoprecipitation. A total of 19 (Δ) out of the 27 reported substrates are identified and each 
carries a SAINT score of ≥ 0.90. SCF subunits (*), such as βTrCP2, Skp1, Rbx1 and Cul1, also have SAINT scores of ≥ 0.90.  
  
 2
Table S1. Reported phosphodegron motifs for βTrCP2. Forty-seven phosphodegron motifs were extracted from previously 
reported βTrCP2 substrates and used for building a consensus motif with MEME. The resulting consensus motif was subsequently 
used for FIMO analysis of the human SwissProt database to identify similar motifs in the human proteome. The corresponding FIMO 
p-value and the ranking, taking into account all the putative degrons generated from the human proteome (FIMO p ≤ 1e-3), are also 
included. (* - degron is not WD40-binding; NA- not identified in FIMO analysis). 
 
 
UniProt 
Acc. No. Gene Symbols Degron Motifs 
Degron 
Range 
FIMO 
p-value 
-Log10 
(p-value) 
Ranking 
based on 
p-value 
1 O00418 eEF2K (21) NSGDSGYPSE 437-446 7.07E-09 8.151 1 
2 P16471 PRLR (58) PDTDSGRGSC 345-354 1.80E-08 7.745 2 
3 O95863 SNAI1/SNAIL (59) SDEDSGKGSQ 92-101 1.89E-08 7.724 3 
4 P18848 ATF4 (60, 61) SDNDSGICMS 215-224 2.83E-08 7.548 5 
5 Q96T88 UHRF1 (62) SDTDSGCCLG 91-100 3.80E-08 7.420 9 
6 P35222 CTNNB1 (19) SYLDSGIHSG 29-38 6.55E-08 7.184 11 
7 Q9UKT4 FBXO5/EMI1 (63) LYEDSGYSSF 141-150 1.42E-07 6.848 16 
8 P30304 CDC25A (64) ESTDSGFCLD 78-87 2.69E-07 6.570 26 
9 Q15653 NFKBIB/IKBB (65) EWCDSGLGSL 15-24 2.93E-07 6.533 28 
10 Q8IYD8 FANCM (66) NVLDSGYNSF 940-949 2.96E-07 6.529 29 
11 Q53EL6 PDCD4 (15) SSRDSGRGDS 67-76 3.18E-07 6.498 31 
12 E3WEB5 YAP1 (67) DESTDSGLSMS 396-405 3.33E-07 6.478 32 
13 Q9HAW4 CLSPN (14) SPSDSGQGSY 26-35 3.49E-07 6.457 34 
14 O00221 NFKBIE (65) SQYDSGIESL 153-162 5.90E-07 6.229 50 
15 O15534 PER1 (68) NPSTSGCSSE 118-127 6.10E-07 6.215 52 
16 Q16236 NFE2L2/NRF2 (69) NDSDSGISLN 343-348 6.88E-07 6.162 55 
17 Q13127 REST (16) IDEDEGIHSH 1005-1014 9.28E-07 6.032 68 
18 P98174 FGD1 (70) PNRDSGIDSI 279-288 9.38E-07 6.028 69 
19 O43521 BCL2L11 (18) SRSSSGYFSF 90-99 9.99E-07 6.000 75 
20 O15055 PER2 (71, 72) NPSTSGCSSD 91-100 1.12E-06 5.951 80 
21 P10912 GHR (73) KDGDSGRTSC 380-389 1.14E-06 5.943 82 
22 Q8TB45 DEPTOR (74) SCGSSGYFSS 283-292 1.20E-06 5.921 92 
23 Q86T82 USP37 (75) SDEDSGNEDV 854-863 1.44E-06 5.842 100 
24 P17181 IFNAR1 (76) TSQDSGNYSN 531-540 1.68E-06 5.775 110 
25 P30291 WEE1_Site2 (77) SWEEEGFGSS 113-122 1.78E-06 5.750 113 
26 P08047 SP1 (78) LPLDSGAGSE 724-733 2.18E-06 5.662 132 
27 P25963 NFKBIA/IKBA (65, 79) DRHDSGLDSM 28-37 2.44E-06 5.613 148 
28 Q6PGQ7 BORA (80) IQMDSGYNTQ 493-502 2.61E-06 5.583 159 
29 Q9GZV5 WWTR1/TAZ (81, 82) QSTDSGLGLG 310-319 3.21E-06 5.493 192 
30 P19235 EPOR (83) VVSDSGISTD 458-467 3.61E-06 5.442 211 
31 P19838 NFKB1 (84) SVCDSGVETS 923-932 3.64E-06 5.439 213 
32 Q00653 NFKB2 (65) VKEDSAYGSQ 862-871 3.78E-06 5.423 222 
33 Q12959 DLG1 (85) KTKDSGLPSQ 594-603 4.28E-06 5.369 245 
34 Q91572 CPEB1-a (86) DSDTSGFSSG 187-196 4.48E-06 5.349 249 
35 Q8C0T5 SIPA1L1/SPIN (87) TSADSGIDTA 1301-1310 8.92E-06 5.049 402 
36 O00444 PLK4 (88) DSIDSGHATI 281-290 3.79E-05 4.421 1213 
37 K7EQT1 FZR1/CDH1 (89) SSPDDGNDVS 137-146 4.51E-05 4.346 1401 
38 P01106 MYC (90) KRSESGSPSA 275-284 4.63E-05 4.334 1425 
39 Q14103 HNRPD/AUF1 (91) HSNSSPRHSE 79-88 4.72E-05 4.326 1450 
40 P30305 CDC25B (92) TEEDDGFVDI 265-274 1.11E-04 3.955 2930 
41 P04637 TP53 (93) EPGGSRAHSS 358-367 1.49E-04 3.827 3776 
42 Q15672 TWST1 (94) PADDSLSNSE 21-30 1.49E-04 3.827 3777 
43 Q07820 MCL1 (95) TSTDGSLPST 154-163 2.21E-04 3.656 5217 
44 P30291 WEE1 (77) TGEDSAFQEP 49-58 3.93E-04 3.406 8299 
45 Q15717 ELAVL1/huR (96) TNYEEAAMAI 293-302 8.69E-04 3.06 15928 
46 Q9NS23 RASSF1-C (97) *STTSSGYCSQ 15-24 NA NA NA 
47 P05923 Vpu (98) RAEDSGNESE 48-57 NA NA NA 
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Table S6. Performance metrics of reproducibility testing. A comparison of performance and reproducibility metrics of 
the current AP-MS (dataset 1) and those obtained from past experiments (dataset 2). Dataset 2 was acquired using 
identical AP methods, but was further separated using SDS-PAGE, followed by LC-MS/MS analysis with an older 
version Orbitrap mass analyzer. Both datasets were analyzed with the same software and settings.  
  
AP-MS 
Dataset 1 
AP-MS 
Dataset 2 
Overlapping 
Proteins 
Percentage 
Overlapping 
(%) 
Number Proteins Identified  1627 725 531 73.24 
Number of Proteins passing CRAPome 
filters (putative substrates) 221 47 31 65.96 
Validated putative substrates (eEF2K, 
RAPGEF2 and TFAP4) passing 
CRAPome filters 
3 3 3 100.00 
Reported Substrates Identified 27 25 21 84.00 
Reported Substrates Identified and 
passing CRAPome filters 20 13 12 92.31 
 
Supplementary tables supplied as Excel files 
Table S2. List of 17,779 predicted phosphodegron motifs in human proteome. A total of 17,779 putative degron 
sequences were extracted from the human proteome with FIMO (p ≤ 1e-3) on the basis of their similarity to the 
phosphodegron consensus motif obtained from MEME. Data include the FIMO p-values, FIMO q-values, evolutionary 
conservation scores, and reported phosphorylation and ubiquitylation site information derived from PhosphoSitePlus. 
(2005882_tableS2.xlsx) 
 
Table S3. List of the proteins isolated by immunoprecipitation, categorized by CRAPome values and sorted into 
the reported substrates and putative substrates (data set 2). (A)  A total of 1,626 proteins identified in the AP-MS 
experiments from three different βTrCP2 constructs, together with their individual SAINT probability scores and also FC-
A and FC-B scores computed with the CRAPome software suite. (B) A subtable exported from Table S3A of the 27 
reported substrates identified in the AP-MS experiments. (C) A subtable exported from Table S3A of the 338 putative 
substrates (after validation by the CRAPome workflow) from the proteins identified in the AP-MS experiments.  
(2005882_table S3.xlsx) 
 
Table S4. List of the proteins isolated by immunoprecipitation, categorized by Perseus values and sorted into the 
reported substrates and putative substrates. (A) A total of 1,626 proteins identified in the AP-MS experiments from 
three different βTrCP2 constructs together with their t-test significance, t-test difference, and p-values after validation with 
the Perseus workflow. (B) A subtable exported from Table S4A of the 27 reported substrates identified in the AP-MS 
experiments. (C) A sub-table exported from Table S3A of the 317 putative substrates (after validation by the Perseus 
workflow) from the proteins identified in the AP-MS experiments. 2005882_table S4.xlsx 
 
Table S5. List of proteins isolated by immunoprecipitation comparing wild-type βTrCP2 with R447A mutant, 
categorized by CRAPome values (data set 1 or old data set). A total of 725 proteins were identified in the AP-MS 
experiments of βTrCP2 (wildtype and R447A mutant) and collated with their individual SAINT probability scores and FC-
A and FC-B scores computed with the CRAPome software suite. 2005882_table S5.xlsx 
 
Table S7. List of putative substrates validated by both CRAPome and Perseus analyses combined with 
bioinformatics analyses. (A) The 221 putative substrates validated by both CRAPome and Perseus analyses after 
combining with bioinformatics prediction in which each candidate must contain a putative degron motif (FIMO p ≤ 1E-3) 
with a conservation score ≥ 0.7. (B) The 221 putative substrates divided into 6 bins according to their FIMO p-values. 
2005882_table S7.xlsx 
